Brief: Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy In First-Line Biliary Tract Cancer Harmoni-Gi1 Meets Primary Endpoint
25/08/2026 22:08
BRIEF-Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy In First-Line Biliary Tract Cancer Harmoni-Gi1 Meets Primary Endpoint Aug 25 (Reuters) - Akeso Inc 9926.HK:
IVONESCIMAB PLUS CHEMOTHERAPY DEMONSTRATES SIGNIFICANT OVERALL SURVIVAL BENEFIT VERSUS DURVALUMAB PLUS CHEMOTHERAPY IN FIRST-LINE BILIARY TRACT CANCER: HARMONI-GI1 MEETS PRIMARY ENDPOINT
AKESO - STUDY MEETS KEY SECONDARY ENDPOINTS OF PROGRESSION-FREE SURVIVAL AND OBJECTIVE RESPONSE RATE
AKESO - HARMONI-GI1 FIRST PHASE III STUDY TO SHOW SIGNIFICANT OS BENEFIT VERSUS GLOBAL STANDARD IN BILIARY TRACT CANCER
Source text: ID:nPn97bfjDa
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals